$ 6.45
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of ATAI is 12 and suggests 84% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
